Immunovant, Inc. (IMVT) Financials

IMVT Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 711.4 million 32.1 million
2023-09-30 292.1 million 40.3 million
2023-06-30 351.2 million 51.4 million
2023-03-31 405.8 million 43.3 million

IMVT Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -47.2 million 10.2 million
2023-09-30 -60.1 million 10.5 million
2023-06-30 -47.4 million 10.7 million
2023-03-31 -55.8 million 7.5 million

IMVT Net Income

No data available :(

IMVT Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 690.9 million - 306000
2023-09-30 269.9 million - 614000
2023-06-30 330.0 million - 919000
2023-03-31 376.5 million - 1.2 million

IMVT Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 144.5 million
2023-09-30 131.2 million
2023-06-30 130.5 million
2023-03-31 129.6 million

IMVT Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 131000 48.3 million 13.2 million -
2023-09-30 34000 48.0 million 13.8 million -
2023-06-30 45000 50.6 million 15.4 million -
2023-03-31 26000 51.8 million 12.4 million -

IMVT Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - 58000
2023-09-30 - 349000
2023-06-30 - 343000
2023-03-31 - 341000

IMVT

Price: $29.06

52 week price:
17.53
45.58

Earnings Per Share: -1.81 USD

P/E Ratio: -17.82

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 791496

Market Capitalization: 4.2 billion

Links: